Drug Profile
LY 2969822
Alternative Names: LY-2969822Latest Information Update: 19 May 2016
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Metabotropic glutamate receptor 2 agonists; Metabotropic glutamate receptor 3 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 12 Dec 2013 Preclinical trials in Undefined indication in USA (PO)
- 12 Dec 2013 Eli Lilly plans a phase I trial in Healthy volunteers in Singapore (NCT02018887)